Nanosizing of a poorly soluble drug: technique optimization, factorial analysis, and pharmacokinetic study in healthy human volunteers.

Ibrahim Elsayed, Aly Ahmed Abdelbary, Ahmed Hassen Elshafeey
Author Information
  1. Ibrahim Elsayed: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  2. Aly Ahmed Abdelbary: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  3. Ahmed Hassen Elshafeey: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt ; Department of Pharmaceutical Sciences, School of Pharmacy, University of Waterloo, ON, Canada.

Abstract

CONTEXT: Diacerein (DCN) has low aqueous solubility (3.197 mg/L) and, consequently, low oral bioavailability (35%-56%). To increase both the solubility and dissolution rate of DCN while maintaining its crystalline nature, high pressure homogenization was used but with only a few homogenization cycles preceded by a simple bottom-up technique.
METHODS: The nanosuspensions of DCN were prepared using a combined bottom-up/top-down technique. Different surfactants - polyvinyl alcohol, sodium deoxycholate, and sodium dodecyl sulfate - with different concentrations were used for the stabilization of the nanosuspensions. Full factorial experimental design was employed to investigate the influence of formulation variables on nanosuspension characteristics using Design-Expert(®) Software. Particle size (PS), zeta potential, saturation solubility, in vitro dissolution, and drug crystallinity were studied. Moreover, the in vivo performance of the optimized formula was assessed by bioavailability determination in healthy human volunteers.
RESULTS: The concentration of surfactant had a significant effect on both the PS and polydispersity index values. The 1% surfactant concentration showed the lowest PS and polydispersity index values compared with other concentrations. Both type and concentration of surfactant had significant effects on the zeta potential. Formula F8 (containing 1% sodium deoxycholate) and Formula F12 (containing 1% sodium dodecyl sulfate) had the highest desirability values (0.952 and 0.927, respectively). Hence, they were selected for further characterization. The saturated solubility and mean dissolution time, in the case of F8 and F12, were significantly higher than the coarse drug powder. Techniques utilized in the nanocrystals' preparation had no effect on DCN crystalline state. The selected formula (F12) showed a higher bioavailability compared to the reference market product with relative bioavailability of 131.4%.
CONCLUSION: The saturation solubility, in vitro dissolution rate and relative bioavailability of DCN were significantly increased after nanocrystallization. Less time and power consumption were applied by the combination of bottom-up and top-down techniques.

Keywords

References

  1. Pharm Dev Technol. 2014 Jun;19(4):491-500 [PMID: 23731085]
  2. Int J Pharm. 2009 Jul 6;376(1-2):204-12 [PMID: 19426794]
  3. Drug Dev Ind Pharm. 2011 Oct;37(10):1181-91 [PMID: 21449824]
  4. J Pharm Sci. 1963 Mar;52:236-41 [PMID: 13938476]
  5. Eur J Pharm Sci. 2001 May;13(2):123-33 [PMID: 11297896]
  6. Mol Pharm. 2010 Oct 4;7(5):1858-70 [PMID: 20822111]
  7. J Control Release. 1998 Jan 2;50(1-3):31-40 [PMID: 9685870]
  8. Int J Pharm. 2009 Mar 31;370(1-2):202-9 [PMID: 19114097]
  9. Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44 [PMID: 17601629]
  10. Int J Pharm. 2009 Jun 22;375(1-2):107-13 [PMID: 19481696]
  11. Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):211-5 [PMID: 9646283]
  12. Int J Nanomedicine. 2013;8:3927-35 [PMID: 24143097]
  13. Int J Pharm. 2002 Apr 26;237(1-2):151-61 [PMID: 11955813]
  14. Toxicol Pathol. 1996 Jul-Aug;24(4):519-28 [PMID: 8864198]
  15. Int J Nanomedicine. 2008;3(3):295-309 [PMID: 18990939]
  16. Pharm Dev Technol. 2013 May-Jun;18(3):730-5 [PMID: 23033924]
  17. Int J Pharm. 2010 Nov 15;400(1-2):49-58 [PMID: 20801200]
  18. Int J Pharm. 2012 Nov 15;438(1-2):287-95 [PMID: 22989976]
  19. J Hazard Mater. 2008 Feb 28;151(1):171-8 [PMID: 17618738]
  20. J Biomed Nanotechnol. 2013 May;9(5):891-900 [PMID: 23802421]
  21. JAMA. 2013 Nov 27;310(20):2191-4 [PMID: 24141714]
  22. Clin Pharmacokinet. 1998 Nov;35(5):347-59 [PMID: 9839088]
  23. J Pharm Pharmacol. 2004 Jul;56(7):827-40 [PMID: 15233860]
  24. J Pharm Sci. 2009 Jun;98(6):2091-103 [PMID: 18803265]
  25. Int J Nanomedicine. 2012;7:5733-44 [PMID: 23166438]
  26. Int J Pharm. 2004 Nov 22;286(1-2):69-80 [PMID: 15501003]
  27. Int J Pharm. 2001 Feb 19;214(1-2):21-4 [PMID: 11282231]
  28. Nat Rev Drug Discov. 2004 Sep;3(9):785-96 [PMID: 15340388]
  29. Int J Pharm. 2008 Nov 19;364(1):64-75 [PMID: 18721869]
  30. BMC Mol Biol. 2007 Feb 26;8:13 [PMID: 17324259]
  31. Int J Pharm. 2005 Aug 11;299(1-2):167-77 [PMID: 15996838]
  32. J Young Pharm. 2012 Jul;4(3):146-56 [PMID: 23112533]
  33. Drug Dev Ind Pharm. 2007 Dec;33(12):1332-9 [PMID: 18097807]

MeSH Term

Administration, Oral
Adult
Anthraquinones
Anti-Inflammatory Agents
Drug Compounding
Drug Design
Drug Stability
Excipients
Factor Analysis, Statistical
Female
Humans
Male
Nanoparticles
Oral Mucosal Absorption
Particle Size
Reference Values
Solubility
Surface-Active Agents
Suspensions

Chemicals

Anthraquinones
Anti-Inflammatory Agents
Excipients
Surface-Active Agents
Suspensions
diacerein

Word Cloud

Created with Highcharts 10.0.0DCNsolubilitybioavailabilitydissolutionsodiumhomogenizationtechniquefactorialPSconcentrationsurfactantvalues1%F12lowratecrystallinehighpressureusedbottom-upnanosuspensionsusing-deoxycholatedodecylsulfateconcentrationszetapotentialsaturationvitrodrugformulahealthyhumanvolunteerssignificanteffectpolydispersityindexshowedcomparedFormulaF8containing0selectedtimesignificantlyhigherrelativeanalysispharmacokineticstudyCONTEXT:Diacereinaqueous3197mg/Lconsequentlyoral35%-56%increasemaintainingnaturecyclesprecededsimpleMETHODS:preparedcombinedbottom-up/top-downDifferentsurfactantspolyvinylalcoholdifferentstabilizationFullexperimentaldesignemployedinvestigateinfluenceformulationvariablesnanosuspensioncharacteristicsDesign-Expert®SoftwareParticlesizecrystallinitystudiedMoreovervivoperformanceoptimizedassesseddeterminationRESULTS:lowesttypeeffectshighestdesirability952927respectivelyHencecharacterizationsaturatedmeancasecoarsepowderTechniquesutilizednanocrystals'preparationstatereferencemarketproduct1314%CONCLUSION:increasednanocrystallizationLesspowerconsumptionappliedcombinationtop-downtechniquesNanosizingpoorlysolubledrug:optimizationdiacereinnanocrystals

Similar Articles

Cited By (22)